Search

Displaying results 2261 - 2270 of 3889 in total
  1. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose

  2. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  3. Drug

    Amaranthus retroflexus whole

    go.drugbank.com/drugs/DB10930
    Approved

    Amaranthus retroflexus whole allergenic extract is used in allergenic testing.

    Mixtures: Treatment Set TS345380
  4. Target

    Lys-63-specific deubiquitinase BRCC36

    go.drugbank.com/bio_entities/BE0009071
    TargetHumans

    Does not have activity toward 'Lys-48'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). … Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193).

    Synonyms: BRCA1-A complex subunit BRCC36, BRISC complex subunit BRCC36
  5. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

  6. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    Engaging several penicillin-binding proteins at once produces bacterial killing that persists even against organisms whose beta-lactamases zidebactam does not inhibit, including metallo-beta-lactamase

  7. Drug

    Pilavapadin

    go.drugbank.com/drugs/DB21552
    Investigational

    Pilavapadin is under investigation in clinical trial NCT06203002 (A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)).

  8. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral cont...

  9. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  10. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound